A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

This is a Phase 1, open-label, multicenter, multiple-dose study to evaluate aumolertinib in European participants with a confirmed diagnosis of activating EGFR mutation positive (EGFRm+) locally advanced or metastatic NSCLC.

Trial Details

NCT ID
NCT07130916
Phase
PHASE1
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Aumolertinib
Locations (sample)
  • Banja Luka, Bosnia and Herzegovina|44.77879,17.20629
  • Mostar, Bosnia and Herzegovina|43.34333,17.80806
  • Sarajevo, Bosnia and Herzegovina|43.84864,18.35644
  • Zenica, Bosnia and Herzegovina|44.20169,17.90397
  • Sofia, Grad, Bulgaria|42.69751,23.32415

Key Eligibility Criteria

  • Male or female European participants (inhabitant of a European country and of European descent) must be ≥ 18 years of age, at the time of signing t…
  • Histological or cytological confirmation diagnosis of newly diagnosed locally advanced (clinical stage IIIB or IIIC) or metastatic (clinical stage …
  • NOTE: if small cell elements are present, the participant is ineligible.
  • Prior anti-tumor systemic therapy. Participant must fulfill one of below:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →